Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Muscle Nerve. 2018 Jan 8;57(5):814–820. doi: 10.1002/mus.26025

Figure 1. Effects of NT-1654 on EAMG manifestation.

Figure 1

(A) Clinical scores were recorded for rats randomly assigned to the healthy control group (Naïve controls [no vehicle or NT-1654 treatment]), the EAMG + vehicle group (EAMG rats treated with PBS), the EAMG + NT-1654 (2 mg/kg) group (EAMG rats treated with 2 mg/kg NT-1654), and the EAMG + NT-1654 (6 mg/kg) group (EAMG rats treated with 6 mg/kg NT-1654). (B) Body weight measurements for each group of rats as a percentage of body weight on day 1. Data are expressed as mean ± s.e.m.; n = 12 rats per group; *p<0.05; **p<0.01.